BACKGROUND: Technological advancements of left ventricular assist devices (LVAD) have created today's potential for extending the lives of patients with end-stage heart failure. Few studies have examined the effect of LVAD therapy on patient-reported outcomes (PROs), such as health status, quality of life, and anxiety/depression, despite poor PROs predicting mortality and rehospitalization in patients with heart failure. In this systematic review, we provide an overview of available evidence on the impact of LVAD therapy on PROs and discuss recommendations for clinical research and practice. METHODS AND RESULTS: A systematic literature search identified 16 quantitative studies with a sample size ≥10 (mean±SD age=50.1±12.6 years) that examined the impact of LVAD therapy on PROs using a quantitative approach. Initial evidence suggests an improvement in health status, anxiety, and depression in the first few months after LVAD implantation. However, PRO scores of patients receiving LVAD therapy are still lower for physical, social, and emotional functioning compared with transplant recipients. These studies had several methodological shortcomings, including the use of relatively small sample sizes, and only a paucity of studies focused on anxiety and depression. CONCLUSIONS: There is a paucity of studies on the patient perspective of LVAD therapy. To advance the field of LVAD research and to optimize the care of an increasingly growing population of patients receiving LVAD therapy, more well-designed large-scale studies are needed to further elucidate the impact of LVAD therapy on PROs.
BACKGROUND: Technological advancements of left ventricular assist devices (LVAD) have created today's potential for extending the lives of patients with end-stage heart failure. Few studies have examined the effect of LVAD therapy on patient-reported outcomes (PROs), such as health status, quality of life, and anxiety/depression, despite poor PROs predicting mortality and rehospitalization in patients with heart failure. In this systematic review, we provide an overview of available evidence on the impact of LVAD therapy on PROs and discuss recommendations for clinical research and practice. METHODS AND RESULTS: A systematic literature search identified 16 quantitative studies with a sample size ≥10 (mean±SD age=50.1±12.6 years) that examined the impact of LVAD therapy on PROs using a quantitative approach. Initial evidence suggests an improvement in health status, anxiety, and depression in the first few months after LVAD implantation. However, PRO scores of patients receiving LVAD therapy are still lower for physical, social, and emotional functioning compared with transplant recipients. These studies had several methodological shortcomings, including the use of relatively small sample sizes, and only a paucity of studies focused on anxiety and depression. CONCLUSIONS: There is a paucity of studies on the patient perspective of LVAD therapy. To advance the field of LVAD research and to optimize the care of an increasingly growing population of patients receiving LVAD therapy, more well-designed large-scale studies are needed to further elucidate the impact of LVAD therapy on PROs.
Authors: Christopher S Lee; Jill M Gelow; Christopher V Chien; Shirin O Hiatt; Julie T Bidwell; Quin E Denfeld; Kathleen L Grady; James O Mudd Journal: J Cardiovasc Nurs Date: 2018 Mar/Apr Impact factor: 2.083
Authors: Himali Weerahandi; Nathan Goldstein; Laura P Gelfman; Ulrich Jorde; James N Kirkpatrick; Judith Marble; Yoshifumi Naka; Sean Pinney; Mark S Slaughter; Emilia Bagiella; Deborah D Ascheim Journal: J Pain Symptom Manage Date: 2016-07-09 Impact factor: 3.612
Authors: Julie T Bidwell; Karen S Lyons; James O Mudd; Jill M Gelow; Christopher V Chien; Shirin O Hiatt; Kathleen L Grady; Christopher S Lee Journal: J Cardiovasc Nurs Date: 2017 Sep/Oct Impact factor: 2.083
Authors: Emily M Rosenberger; Kristen R Fox; Andrea F DiMartini; Mary Amanda Dew Journal: Curr Opin Organ Transplant Date: 2012-10 Impact factor: 2.640